GH Research Awaits Key FDA Decision on GH001 as Phase 3 Depression Trial Advances
Market Chameleon (Mon, 5-Jan 10:31 AM)
FDA Greenlights GH001 for U.S. Trials—Phase 3 Launch Set for 2026 as Rapid-Acting Antidepressant Shows Promise
Market Chameleon (Mon, 5-Jan 7:05 AM)
